Estimating Cost Functions for Resource Allocation Using Transmission Models: A Case Study of Tuberculosis Case Finding in South Africa. by Gomez, Gabriela B et al.
Highlights  
• Mathematical and economic modelling is being used to inform how disease control 
resources are allocated and what policies are adopted. These models specify complex 
non-linear relationships between service coverage and impact. However, functions 
describing the relationship between costs and service volume have typically been less 
sophisticated, assuming constant marginal costs of expanding service coverage. This 
approach runs counter to the theoretical understanding of the way costs behave when 
scaling up.  
• We propose an alternative approach. We developed a mechanistic framework to estimate 
total costs for inclusion in model-based economic evaluations using a combination of 
secondary data from small-scale costing studies and routine reporting systems. We 
provide a pragmatic, mechanistic framework rooted in economic theory for others facing 
similar data constraints to improve resource allocation models used to define packages of 
interventions within LMIC settings.  
• Using a case study of tuberculosis case detection in South Africa, we show that the 
functional form chosen to estimate total costs will determine the magnitude of total costs 
when increasing the outputs and coverage. In turn, these differences can impact policy 
choice and resource allocation decisions. The framework presented here is a first step 
towards a more transparent and empirically based cost modelling approach to better 






In the context of Universal Health Coverage (UHC), increased attention is being placed on 
priority setting both across and within disease-specific programs, to ensure funds are allocated 
efficiently to maximize impact. Supported by development funders, mathematical (disease 
transmission) and economic modelling are being increasingly used to inform prioritisation 
processes and evaluate strategies for achieving target coverage levels for infectious disease 
programmes (some recent examples include [1]–[3]). These models typically predict the impact 
and cost-effectiveness of combinations of coverage of a range of disease-specific interventions. 
They are either used to optimise cost-effectiveness under a budget constraint (constrained 
optimisation) or to report incremental cost-effectiveness ratios that compare competing policy 
portfolios. 
 
Disease transmission models explore complex and sophisticated non-linear relationships between 
service coverage and epidemiological impact (health benefits). However, they have often 
assumed constant marginal costs when modelling expanding service coverage, with exceptions 
being [4]–[6]. A linear approach runs counter to economic theory describing how costs behave 
under changes in the production process, overlooking economies of scale and scope. These 
economies are the conditions under which long-run unit costs decrease as output increases or as 
the range of services expands, respectively. Economies of scale and scope are due because fixed 
costs such as buildings or utilities are spread over larger patient volumes, facilities become more 
efficient through specialisation and shared inputs such as human resources are utilised over a 
larger number of services. In recent years, several large-scale empirical costing studies have been 
conducted, particularly in the area of HIV and immunization. These studies have suggested that 
the relationship between marginal costs, scale and population-level coverage is likely to be non-
linear (for example [7]–[10]). This evidence undermines the assumption of linear marginal costs 
typically used in disease transmission models, and suggests that other functional forms for cost 
calculation should be considered [4]. However, identifying and characterising cost functions has 
been a challenge in practice, as both cost accounting identities and flexible cost functions have 
proven difficult to parameterise [4]. Empirically deriving cost functions using econometric 
methods is a substantial and costly undertaking, particularly where comprehensive multi-site cost 
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data is not available through routine systems. In addition, cross-sectional surveys of costs may 
not well predict longitudinal variation in costs due to an increase in scale. Theoretically-defined 
cost functions linking longitudinal expenditure data to coverage levels can also be used. 
However, expenditures may be partial estimates of cost and available data on service outputs 
may be insufficient to fit these functions in many low- and middle-income country (LMIC) 
settings [11].  
 
As an alternative approach, we propose a mechanistic mathematical framework to estimate total 
costs for inclusion in transmission model-based economic evaluations. We use a combination of 
secondary data from small scale costing studies and routine reporting systems. Our approach 
aims to disaggregate both site-level (costs incurred at point of service) and above-site-level 
(costs incurred at a higher organisational level – at district or national) costs. It allows for scope 
and scale effects in the estimation of total incremental costs of different interventions. We 
applied this framework to a model previously used to inform resource allocation in tuberculosis 
(TB) [12], to illustrate both the data requirements and assumptions. We aim to provide a 
pragmatic, mechanistic framework rooted in economic theory. The purpose of such a framework 
is to improve resource allocation models used by analysts facing time and data constraints and 
aiming to define packages of interventions within disease-specific programs.  
 
2 Conceptual framework 
 
Economic theory posits that technologies and production processes can have varying returns to 
scale. The variation in returns to scale will be different whether we analyse production costs in 
the short run (the period where some of the factors of production are fixed) or the long run (when 
all factors of production are variable). For example, in the short run, it may not be possible to 
change the size or numbers of health facilities in each area. But the level of service coverage may 
be increased by increasing variable factors such as number of staff within the existing facilities. 
Typically, disease-specific program expansion (such as in vertical HIV and TB programs) is 
characterised using a short run cost function. This is motivated by (a) a payer perspective that is 
often focused on the single disease, limiting the decision space to varying only those factors of 
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production that are under the control of the vertical program; and (b) relatively short planning 
cycles of three to five years. 
 
The (short-run) average cost function is commonly assumed to have a u-shape. With increasing 
scale, average costs decrease. This is because the fixed component is divided among increasing 
units of production until the point where operating at high levels of capacity starts to constrain 
the efficiency of the production process, for example because no additional patients can be 
screened without opening new laboratories to process diagnostic tests. After this point, average 
costs begin to rise. In this case, a short run cost function for each provider will have the 
following form:  
𝐶𝑠(𝑦, 𝑥2) =  𝑤1𝑥1 + 𝑤2𝑥2; such that 𝑓(𝑥1, 𝑥2) = 𝑦 (equation 1) 
 
Where 𝑦 is the unit of output, 𝑤1 and 𝑤2 are prices, 𝑥1 are the variable factors of production, and 
𝑥2is the fixed factor of production. 
 
However, interventions are expanded by disease programmes across a fixed network of service 
providers. The field of transportation economics provides a relevant approach to understanding 
the form of cost function that is appropriate for a disease programme[13]. Here economies of 
scale are determined by economies of capacity utilisation, the relationship between cost and the 
capacity of each vehicle, i.e. how full is each plane (or health service provider); and economies 
of density, the relationship between cost and density of use of the network structure, i.e. how 
many planes (or health service providers) are used to provide the service, keeping the capacity of 
planes constant.  
 
We postulate that a cost function, in the case of scale-up of disease-specific services, should be 
derived both by considering the relationship between the number and type of facilities (density of 
provision), and the number of people serviced at each facility (capacity utilisation). The pattern 
of programme expansion through the health service network has been shown to have an impact 
on the distribution of costs over time [4]. Local knowledge and input will help framing the 
calculations, whether programme expansion is through stand-alone campaigns or facility-based; 
whether large facilities join the scale-up first, followed by smaller facilities; or whether there is a 
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regional variation in scale-up strategies. Additionally, strategies within disease areas may exhibit 
economies of scope between service areas that de facto expand capacity at the facility level in 
reducing costs from joint production of services.  
 
Following these principles, we start by proposing a simple cost function in the form of an 
adapted accounting identity that captures density (number of facilities expanding services linked 
to the pattern of program expansion) and capacity (number of people receiving the service in 
each facility) across levels of outputs. In this model, we assume a centrally-coordinated disease 
control programme, where services are provided by many service outlets (e.g. clinics and 
hospitals). The form of total costs (TC) per strategy considered in the short run should be as 
follows:  
𝑇𝐶 = 𝐹𝑃 + ∑ 𝐹𝐹𝑖𝑖∈𝐼 + ∑ (𝑉𝐹 x 𝑛_𝑜𝑢𝑡𝑝𝑢𝑡)𝑖𝑖∈𝐼  (equation 2) 
 
Where FP= fixed programme cost; FFi=fixed facility cost for facility i; VFi=variable facility cost 
for facility i; n_outputi=number of outputs for facility i, i = total number of facilities. 
 
We define fixed programme cost as an investment at a national level by the programme to 
manage the intervention or its continuous service delivery. Facility-level fixed costs (in the short 
run) differ by facility, but are variable at national level (as a function of the number of facilities). 
These facility-level fixed costs include building costs or management costs. They can also 
include ‘programme’ costs that are incurred above the site level, but are fixed by facility, such as 
supervision and training. Facility-level variable costs are all those costs that change as output 
levels change, for example consumables (such as HIV test kits and sputum tests).  
 
When programmes expand, they can also produce economies of scope due to integration of 
services or the use of same inputs to produce joint outputs. There are various sources of 
economies of scope, we focus on influence of joint production on fixed costs. Here we postulate 
that some fixed costs can be incurred to deliver simultaneously more than one output. We only 
consider economies of scope operating from the intervention standpoint and only considered 
incremental costs for those activities delivered jointly with other programmes (for example, TB 
screening of antiretroviral treatment patients during monitoring visits for HIV care). To reflect 
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these joint costs, we defined fixed and variable costs at facility-level in intervention-facility 
pairs, if only fixed costs are influenced by scope expanding equation 2 to: 
 
𝑇𝐶 = 𝐹𝑃𝑗 + ∑ ∑ 𝐹𝐹𝑖𝑗𝑖∈𝐼𝑗∈𝐽 − ∑ 𝐹𝐹𝑠ℎ𝑎𝑟𝑒𝑑 𝑖𝑖∈1 + ∑ ∑ (𝑉𝐹 x 𝑛_𝑜𝑢𝑡𝑝𝑢𝑡𝑠)𝑖𝑗𝑖∈𝐼𝑗∈𝐽  (equation 3) 
 
Where FP= fixed programme cost for intervention j; FFij=fixed facility cost for facility i and 
intervention j; FF_sharedi = fixed facility costs shared between 2 or more interventions; VFi = 
variable facility cost for facility i and intervention j; n_outputij=number of outputs for facility i 
and intervention j; I = total number of facilities; J = total number of interventions. 
 
Equation 3 allows fixed costs at the programmatic and site level to be distinguished and allows 
for densities of scale across multiple service providers.  
 
3 Case Study 
We conducted a case study to illustrate the empirical application and data requirements for 
disease transmission models (epidemiological mathematical models of infectious diseases 
commonly used in economic evaluations). Using existing empirical work to support National 
Strategic Plans for tuberculosis in South Africa, we compare three scenarios: 1) linear cost 
function (conventional approach): average costs remain the same during scale-up; 2) uniform 
facility-level cost function, including economies of capacity and scope, assuming a uniform 
scale-up across facilities; and 3) density cost function, including economies of capacity, scope 
and density where larger facilities increase service outputs in the first instance, then they are 
followed by smaller facilities joining programme expansion.  
 
Our case study was provided by the TB Modelling and Analysis Consortium (TB MAC)[14], as 
part of an analysis examining the feasibility of achieving the 2025 goals of the WHO ‘End TB 
strategy 2016-2035’ in three countries: China, India, and South Africa [12]. This analysis 
compared several interventions along the TB care cascade (prevention, case finding, diagnosis 
and treatment). Cost functions were defined as linear relationships, with a constant marginal cost 
per additional unit of output. In South Africa, it was found that while no single intervention 
scenario was sufficient to reach the epidemiological targets by 2025, a combination of all 
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interventions could potentially be [15]. From a societal perspective, expanded TB control 
substantially reduced patient-incurred costs and helped avert household catastrophic costs [16]. 
From a healthcare payer perspective, most interventions appeared highly cost-effective compared 
to conventional willingness-to-pay thresholds, yet considerable budget increases would be 
needed to achieve the ambitious scale up [12].  
 
In this study, we expand the previous analysis to compare three proposed approaches to cost 
functions. We examine the scale up of TB symptom screening for all patients attending primary 
care clinics, followed by current diagnosis algorithm for those found to be symptomatic. We 
focused on a case finding intervention because this intervention was the main driver of total costs 
in the previous analysis [12].  
 
3.1 Specification of joint production functions for intervention and services  
First, we defined outputs from the disease transmission model for each intervention and service. 
Outputs were defined as all the units that will have costs attached to them – for example, number 
of people tested, number of person-months on treatment. These outputs are related to the 
intervention examined in that they are expected to change directly as a result of the intervention 
(i.e. number of people screened and number of people tested), but also consequential outputs 
along the TB care cascade (i.e. number of people treated if more people are diagnosed following 
an expansion of screening activities).  
 
In consultation with local policy makers, we defined the production process for each output, in 
terms of activities directly related to the intervention, supporting services needed to achieve 
implementation coverage targets, and health system level where these activities take place. 
Intervention activities include, for example, nurse time for TB symptom screening and test costs 
for TB diagnosis; supporting services will be outreach activities, staff training at facilities being 
recruited into the programme, and health system level activities considered could include 
information technology systems for tracking diagnoses. In order to do this, we looked at the main 
factors of production for each output and the resources required by the facilities to start offering 




We then estimated total costs as a function of disaggregated average costs into the following 
components: programme costs (assumed fixed each year), facility-level fixed costs, and variable 
costs at facility level as per equations above. All data on unit costs were sourced from the 




3.2 Specification of programme expansion patterns  
To illustrate the difference in total costs estimations, we calculated and compared incremental 
costs (compared to a base case of no screening intervention) under three assumption scenarios:  
- Linear assumption of costs: scenario 1 
- Cost functions applying economies of capacity utilisation: scenario 2 
- Cost functions applying economies of capacity utilisation and density: scenario 3 
 
In figure 1, we present a step-by-step description of the link between the conceptual framework 
and the calculation of costs for each scenario. Data on the primary health care facility sizes in 
South Africa were obtained from the National Department of Health, specifically from the 
National Health Information System [17]. The database included number of patients attending 
outpatient services per facility. For scenario 2, we modelled programme expansion across 
facilities by assuming service volume would be increased proportionally to the site size within 
each site (defined as the number of patients attending outpatient services). This scenario reflects 
the intrinsic assumption in the previous analysis [12], which is that the TB program is facing 
partially exogenous fixed costs, in that the total number of facilities available nationally remains 
fixed while the size of facilities changes, without limiting the ability of facilities to absorb the 
additional demand for services. However, we include economies of scale and scope at facility 
level. In a third scenario, we varied the pattern of recruitment into the programme for facilities 
and assumed that the programme started expanding from larger facilities (as these are assumed to 
be recruited earlier in a new programme or programme expansion) to smaller ones. All facilities 






We present total costs and the difference between scenario 1 and 2, and then 2 and 3.  
 
4 Discussion 
In figure 2a, we present the incremental costs under three cost assumption scenarios. We observe 
reductions in incremental costs due to the inclusion of economies of capacity (over 20% 
reduction); however, the addition of economies of density did not show major impact in 
comparison (less than 5% reduction). In figure 2b, we present the difference between these 
scenarios. The differences between scenarios are due to the assumptions in economies of scale 
(and scope). The small differences between scenarios reflect the impact of sharing fixed site 




Cost data availability and quality was an issue when parameterising costs functions.  
Detailed cost data to fit cost functions empirically exists but these are rare as detailed cost 
estimates at different stages of implementation and time points are needed for a large sample 
size. Cost data requirements for the proposed approach were less onerous than those for 
parameterising cost functions empirically, see table II. Comprehensive, standardised and 
disaggregated unit costs (for a limited number of outputs) are a pre-requisite. Information on the 
network of facilities available to the programme (including type and size of the facility) is 
usually available centrally at country-level. Finally, descriptive and detailed information on 
services, intervention and ancillary activities needed to expand coverage as well as planned 




The assumption of a linear relationship between costs, scale and pattern of programme expansion 
can change the total predicted costs in the presence of economies of density and/or capacity 
utilization. The extent to which all these should be considered and whether they will matter for 
priority setting depends on the intervention considered and services evaluated. While economies 
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of capacity (or scale at facility level) and scope can substantially change the total cost estimates 
over time, assumptions on how the program expands within the network of facilities (economies 
of density) did not seem to have a major impact on cost estimates over time in our case example. 
Consideration on whether to include economies of density will depend on the intervention 
evaluated. In our case study, delivery of intensified case finding for TB is an intervention with 
(relatively) low fixed costs, both at facility and programme levels, particularly in a setting such 
as South Africa where facilities have low spare capacity. The relative proportion of fixed costs 
that are incurred at programme level compared to facility level could help explain the difference 
in our results compared to previous studies. Indeed, previous studies have shown that the 
inclusion of economies of scale has an impact on the resulting prioritisation [4]–[6]. In addition, 
these studies highlighted that assumptions on the proportion of fixed costs or pattern of 
programme expansion does influence the total costs estimates. These two assumptions are made 
explicit in this framework.  
 
Our case study presents the introduction of one intervention in South Africa and illustrates the 
impact of several assumptions of programme scale-up. We expect results to vary in other cases 
and with other assumptions. Whether to use more complex cost functions including economies of 
capacity or density would be then a decision based on whether the intervention considered has 
high fixed costs or other reasons to expect strongly non-linear cost functions.  
  
This framework has the advantage of being transparent and based on available, routinely 
collected data. However, there are intrinsic differences between transport and health economics. 
Three areas for consideration in cost formation are supply and demand constraints, as well as 
quality of care. Firstly, health system-wide constraints could be better defined. For example, 
more information is needed to characterise the distribution of spare human resource capacity and 
how this capacity can be reallocated. Supply-side constraints may be heterogeneously distributed 
across the care cascade. This differential distribution can be accounted within the joint 
production function by limiting the overall scale to the capacity of the service that is constrained. 
This would be one approach among several that could be applied in economic evaluations, an 
example could be found here [18]. Furthermore, our framework does not investigate the variation 
of costs due to quality of services. We recognise that quality of care can vary both between levels 
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of the health system and between different facilities at the same level (e.g. rural vs urban, new vs 
old). These differences become central to efficiency analyses across unit costs. However, if data 
on how unit costs varied in a specific setting because of differences in operational environment 
such as quality, uptake and accessibility of care, then these could be accommodated within our 
framework by including additional terms for facility-level fixed and variable costs. 
 
By disaggregating fixed costs at the programme and facility level, we allow for different 
densities of scale across multiple service providers, thus extending previous approaches where 
programme and facility level costs are aggregated into ‘platform’ costs [19]. Another limitation 
of this framework is that it focuses on predicting total costs in the short run. Depending on the 
decision-maker perspective, it can be argued that long run cost functions (where all inputs are 
considered variable) would be more appropriate when looking at scaling up interventions. 
Decisions within disease-specific programmes tend not to include changes in infrastructure such 
as building additional facilities. In this context, short run cost functions would reflect this 
perspective.  
 
This framework is based on two key sources of data: 1) empirical cost data reported in a 
disaggregated manner, both by inputs and activities; and 2) facility size data available on the 
network of facilities that will be scaling up the intervention of interest. These data are generally 
available from cross sectional studies, and an implicit assumption in this framework is that 
observed behaviour of costs in a cross-sectional sample of facilities of different sizes can be 
extrapolated to predict behaviour of costs in facilities expanding services longitudinally. Our 
approach reflects a limitation of current data availability. Furthermore, not all disease-specific 
programmes will have cross sectional data available and standardised at facility level. There are 
several ongoing initiatives to improve availability of cost data in a variety of diseases and, in 
particular, the Global Health Cost Consortium (GHCC) has led efforts to standardise HIV- and 
TB-specific costs with additional guidance for reporting standards (including a framework for 
standardisation of interventions, units, activities, and inputs). These reporting standards are part 
of the GHCC’s reference case for costing activities, which is a set of ‘acceptable’ principles and 
methodological guidance on how to achieve those principles, and includes both theory and 




Finally, further research will be needed to expand this framework to include explicit budget 
constraints. This becomes essential when considering equity and efficiency trade-offs, for 
example when a programme can only afford partial scale-up. Our results will then show that 
gains in efficiency could be contrasted with a more equitable scale-up (if we understand smaller 





The functional form an analyst uses to estimate total costs during priority setting exercises will 
determine the magnitude of total costs when increasing outputs and coverage. This, in turn, will 
impact the results of any optimisation routine. Yet, data availability in low- and middle-income 
countries can limit the analysis of costs in economic evaluations. Ultimately, infectious diseases 
modellers and economists should aim to choose rationally the functional form and include more 
transparent and empirically-based cost models into their analyses, as put forward in recently 
published guidance for country-level modelling in tuberculosis [21]. This framework describes a 
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7 Legends and Figure 
Figure 1. Step by step method and equivalent scenario calculation 
Figure 2. Incremental costs by cost estimation scenario (USD 2016) 
Legend 
Panel 2a. Total costs per year in scenario 1 (linear assumption of costs) are shown in columns, while scenarios 2 (cost functions 
applying economies of capacity utilisation) and 3 (cost functions applying economies of capacity utilisation and density) are 
shown in lines (green and red, respectively). There is a reduction observed when adding economies of capacity utilisation 
(difference between scenario 1 vs. scenario 2 and 3). However, the different between scenario 2 and scenario 3 (addition of 
economies of density) is small, shown in panel 2b. Tables 
 
Table I. Definition of units and unit costs per activity – constant and disaggregated (USD 2016). 
Table II. Comparison and data requirements for three approaches to modelling costs for economic evaluations using transmission 
models.  
